A major cause of tuberculosis (TB) resistance to the aminoglycoside kanamycin (KAN) is the Mycobacterium tuberculosis (Mtb) acetyltransferase Eis. Upregulation of this enzyme is responsible for inactivation of KAN through acetylation of its amino groups. A 123 000-compound high-throughput screen (HTS) yielded several small-molecule Eis inhibitors that share an isothiazole S,S-dioxide heterocyclic core. These were investigated for their structure-activity relationships. Crystal structures of Eis in complex with two potent inhibitors show that these molecules are bound in the conformationally adaptable aminoglycoside binding site of the enzyme, thereby obstructing binding of KAN for acetylation. Importantly, we demonstrate that several Eis inhibitors, when used in combination with KAN against resistant Mtb, efficiently overcome KAN resistance. This approach paves the way toward development of novel combination therapies against aminoglycoside-resistant TB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5150266PMC
http://dx.doi.org/10.1021/acschembio.6b00110DOI Listing

Publication Analysis

Top Keywords

potent inhibitors
8
acetyltransferase eis
8
mycobacterium tuberculosis
8
kan acetylation
8
eis inhibitors
8
eis
5
kan
5
inhibitors acetyltransferase
4
eis overcome
4
overcome kanamycin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!